Zhaowei Xu

720 total citations
28 papers, 547 citations indexed

About

Zhaowei Xu is a scholar working on Molecular Biology, Biomedical Engineering and Materials Chemistry. According to data from OpenAlex, Zhaowei Xu has authored 28 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 9 papers in Biomedical Engineering and 8 papers in Materials Chemistry. Recurrent topics in Zhaowei Xu's work include Nanoplatforms for cancer theranostics (9 papers), Advanced Nanomaterials in Catalysis (8 papers) and Ubiquitin and proteasome pathways (5 papers). Zhaowei Xu is often cited by papers focused on Nanoplatforms for cancer theranostics (9 papers), Advanced Nanomaterials in Catalysis (8 papers) and Ubiquitin and proteasome pathways (5 papers). Zhaowei Xu collaborates with scholars based in China, United States and Sweden. Zhaowei Xu's co-authors include Huijian Wu, Xiao‐Yan Bai, Yangyang Yang, Guilong Zhang, Shujing Li, Geng Tian, Xiang Ao, Xiahui Li, Yanan Li and Bowen Li and has published in prestigious journals such as Scientific Reports, Chemical Engineering Journal and ACS Applied Materials & Interfaces.

In The Last Decade

Zhaowei Xu

28 papers receiving 543 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhaowei Xu China 15 294 134 99 91 82 28 547
Shanliang Zheng China 10 264 0.9× 125 0.9× 112 1.1× 90 1.0× 51 0.6× 20 500
Yuanlin Xu China 12 324 1.1× 135 1.0× 162 1.6× 141 1.5× 82 1.0× 33 715
Chien‐Hsiu Li Taiwan 15 258 0.9× 136 1.0× 124 1.3× 110 1.2× 65 0.8× 37 543
Guangyue Shi China 12 358 1.2× 61 0.5× 94 0.9× 42 0.5× 70 0.9× 31 577
Junyu Xiang China 12 374 1.3× 89 0.7× 221 2.2× 88 1.0× 97 1.2× 21 669
Lu Tan China 14 356 1.2× 126 0.9× 84 0.8× 106 1.2× 28 0.3× 33 556
Yangchun Zhou China 9 328 1.1× 160 1.2× 82 0.8× 25 0.3× 66 0.8× 11 516

Countries citing papers authored by Zhaowei Xu

Since Specialization
Citations

This map shows the geographic impact of Zhaowei Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhaowei Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhaowei Xu more than expected).

Fields of papers citing papers by Zhaowei Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhaowei Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhaowei Xu. The network helps show where Zhaowei Xu may publish in the future.

Co-authorship network of co-authors of Zhaowei Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Zhaowei Xu. A scholar is included among the top collaborators of Zhaowei Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhaowei Xu. Zhaowei Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Congmin, Yu Liu, Ying Xim Tan, et al.. (2025). HOGA1 Suppresses Renal Cell Carcinoma Growth via Inhibiting the Wnt/β‐Catenin Signalling Pathway. Journal of Cellular and Molecular Medicine. 29(6). e70490–e70490. 2 indexed citations
2.
Liang, Qi, et al.. (2025). Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers. Biomolecules. 15(6). 763–763. 1 indexed citations
3.
Kong, Demin, Fuyi Xu, Yangyang Yang, et al.. (2025). Hypoxia-triggered ERRα acetylation enhanced its oncogenic role and promoted progression of renal cell carcinoma by coordinating autophagosome-lysosome fusion. Cell Death and Disease. 16(1). 23–23. 1 indexed citations
4.
Kong, Demin, Ying‐Ying Wu, Fuyi Xu, et al.. (2024). CHES1 modulated tumorigenesis and senescence of pancreas cancer cells through repressing AKR1B10. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1870(6). 167214–167214. 4 indexed citations
5.
6.
Xu, Zhaowei, Shuyan Liu, Fuyi Xu, et al.. (2022). Acetylation of Checkpoint suppressor 1 enhances its stability and promotes the progression of triple-negative breast cancer. Cell Death Discovery. 8(1). 474–474. 3 indexed citations
7.
Li, Wenling, Yanan Zhang, Qingdong Li, et al.. (2022). NIR‐II Fluorescence Imaging‐Guided Oxygen Self‐Sufficient Nano‐Platform for Precise Enhanced Photodynamic Therapy. Small. 18(51). e2205647–e2205647. 29 indexed citations
8.
Zhang, Caiyun, et al.. (2022). PDGFB targeting biodegradable FePt alloy assembly for MRI guided starvation-enhancing chemodynamic therapy of cancer. Journal of Nanobiotechnology. 20(1). 264–264. 25 indexed citations
9.
Xiao, Jianmin, Ke Zhou, Hui Chen, et al.. (2021). A nanoselenium-coating biomimetic cytomembrane nanoplatform for mitochondrial targeted chemotherapy- and chemodynamic therapy through manganese and doxorubicin codelivery. Journal of Nanobiotechnology. 19(1). 227–227. 11 indexed citations
10.
Liu, Shuyan, Xiju Wang, Shoujun Yu, et al.. (2020). A Meta-Analysis on the Association Between TNFSF4 Polymorphisms (rs3861950 T > C and rs1234313 A > G) and Susceptibility to Coronary Artery Disease. Frontiers in Physiology. 11. 539288–539288. 4 indexed citations
11.
12.
Chen, Huan, Zhaowei Xu, Xiahui Li, et al.. (2018). α-catenin SUMOylation increases IκBα stability and inhibits breast cancer progression. Oncogenesis. 7(3). 28–28. 8 indexed citations
13.
Xu, Zhaowei, Yangyang Yang, Bowen Li, et al.. (2018). Checkpoint suppressor 1 suppresses transcriptional activity of ERα and breast cancer cell proliferation via deacetylase SIRT1. Cell Death and Disease. 9(5). 559–559. 20 indexed citations
14.
Jia, Zhaojun, Miao Wang, Shujing Li, et al.. (2018). U-box ubiquitin ligase PPIL2 suppresses breast cancer invasion and metastasis by altering cell morphology and promoting SNAI1 ubiquitination and degradation. Cell Death and Disease. 9(2). 63–63. 27 indexed citations
15.
Bai, Xiao‐Yan, Shujing Li, Miao Wang, et al.. (2017). Krüppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion. Cancer Letters. 412. 224–235. 60 indexed citations
16.
Ao, Xiang, Shujing Li, Zhaowei Xu, et al.. (2016). Sumoylation of TCF21 downregulates the transcriptional activity of estrogen receptor-alpha. Oncotarget. 7(18). 26220–26234. 16 indexed citations
17.
Bi, Hai-Lian, Xiao‐Yan Bai, Zhaowei Xu, et al.. (2015). DEC1 regulates breast cancer cell proliferation by stabilizing cyclin E protein and delays the progression of cell cycle S phase. Cell Death and Disease. 6(9). e1891–e1891. 58 indexed citations
18.
Bai, Xiao‐Yan, Xiao Jiang, Zhaowei Xu, et al.. (2015). Association between Dietary Vitamin C Intake and Risk of Prostate Cancer: A Meta-analysis Involving 103,658 Subjects. Journal of Cancer. 6(9). 913–921. 39 indexed citations
19.
Liu, Ying, Xiang Ao, Zhaojun Jia, et al.. (2015). FOXK2 Transcription Factor Suppresses ERα-positive Breast Cancer Cell Growth Through Down-Regulating the Stability of ERα via mechanism involving BRCA1/BARD1. Scientific Reports. 5(1). 8796–8796. 52 indexed citations
20.
Wu, Huijian, Xiang Ao, Ying Liu, et al.. (2015). Association between EHBP1 rs721048(A>G) polymorphism and prostate cancer susceptibility: a meta-analysis of 17 studies involving 150,678 subjects. OncoTargets and Therapy. 8. 1671–1671. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shanliang Zheng Breakdown of academic impact, for papers by Yuanlin Xu Breakdown of academic impact, for papers by Chien‐Hsiu Li Breakdown of academic impact, for papers by Guangyue Shi Breakdown of academic impact, for papers by Junyu Xiang Breakdown of academic impact, for papers by Lu Tan Breakdown of academic impact, for papers by Yangchun Zhou
Rankless by CCL
2026